EW vs. BSX, SYK, MDT, BDX, IDXX, RMD, DXCM, STE, PODD, and BAX
Should you be buying Edwards Lifesciences stock or one of its competitors? The main competitors of Edwards Lifesciences include Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), STERIS (STE), Insulet (PODD), and Baxter International (BAX). These companies are all part of the "health care equipment" industry.
Edwards Lifesciences vs.
Boston Scientific (NYSE:BSX) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.
Edwards Lifesciences received 272 more outperform votes than Boston Scientific when rated by MarketBeat users. Likewise, 70.77% of users gave Edwards Lifesciences an outperform vote while only 69.96% of users gave Boston Scientific an outperform vote.
89.1% of Boston Scientific shares are held by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are held by institutional investors. 0.5% of Boston Scientific shares are held by insiders. Comparatively, 1.3% of Edwards Lifesciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Boston Scientific presently has a consensus price target of $114.87, suggesting a potential upside of 10.01%. Edwards Lifesciences has a consensus price target of $80.20, suggesting a potential upside of 7.22%. Given Boston Scientific's stronger consensus rating and higher possible upside, equities analysts plainly believe Boston Scientific is more favorable than Edwards Lifesciences.
Edwards Lifesciences has a net margin of 72.93% compared to Boston Scientific's net margin of 11.07%. Edwards Lifesciences' return on equity of 19.40% beat Boston Scientific's return on equity.
Edwards Lifesciences has lower revenue, but higher earnings than Boston Scientific. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
Boston Scientific has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.
In the previous week, Boston Scientific had 12 more articles in the media than Edwards Lifesciences. MarketBeat recorded 49 mentions for Boston Scientific and 37 mentions for Edwards Lifesciences. Boston Scientific's average media sentiment score of 1.28 beat Edwards Lifesciences' score of 1.20 indicating that Boston Scientific is being referred to more favorably in the media.
Summary
Boston Scientific beats Edwards Lifesciences on 10 of the 19 factors compared between the two stocks.
Get Edwards Lifesciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edwards Lifesciences Competitors List
Related Companies and Tools
This page (NYSE:EW) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy EW Stock Free EW Stock Alerts